Prelude Therapeutics Inc (PRLD) Stock Analysis

Sector: HEALTHCARE - BIOTECHNOLOGY

Exchange: NASDAQ

Key Metrics

• Price: $2.87
• Market Cap: $206.83M
• EPS: $-1.47
• 52-Week High: $4.22
• 52-Week Low: $0.61

Market Sentiment

Prelude Therapeutics Inc currently has a Neutral sentiment score of 0.02.

About Prelude Therapeutics Inc

Prelude Therapeutics Inc. is a clinical-stage oncology firm headquartered in Wilmington, Delaware, dedicated to the development of precision small molecule therapies targeting pivotal cancer drivers. The company boasts a promising pipeline, underpinned by its proprietary drug discovery platform, which aims to deliver innovative treatment solutions for patients with advanced malignancies. With an emphasis on precision medicine, Prelude is strategically positioned to make significant contributi...

GNG Research provides proprietary Safety Scores, Quality Scores, Fair Value estimates, and Valuation Ratings for Prelude Therapeutics Inc and 4,500+ other companies. Learn more about GNG Pro.

Frequently Asked Questions

Does PRLD pay dividends?

Prelude Therapeutics Inc (PRLD) does not currently pay a regular dividend.

What is PRLD's market cap?

Prelude Therapeutics Inc (PRLD) has a market capitalization of $206.83M with a current stock price of $2.87.